PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35615587-6	2022	Co-treatment with a histamine H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine (FMPH), dose-dependently reduced the increased expression of NLRP3, caspase-1 and GSDMD induced by olanzapine, quetiapine, risperidone, or haloperidol.	fmph	90-94	histamine receptor H1	Homo sapiens	20-41
34228989-5	2021	On the other hand, only the pre-treatment of histamine H1 receptor agonist, FMPH (2, 6.5 mug/mouse, intra-CA1 bilateral) reversed the reduction in locomotor activity induced in ethanol withdrawn mice, wherein other employed histaminergic agents were devoid of any effect on this behavior.	fmph	76-80	histamine receptor H1	Mus musculus	45-66
35615587-6	2022	Co-treatment with a histamine H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine (FMPH), dose-dependently reduced the increased expression of NLRP3, caspase-1 and GSDMD induced by olanzapine, quetiapine, risperidone, or haloperidol.	fmph	90-94	NLR family pyrin domain containing 3	Homo sapiens	150-155
35615587-6	2022	Co-treatment with a histamine H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine (FMPH), dose-dependently reduced the increased expression of NLRP3, caspase-1 and GSDMD induced by olanzapine, quetiapine, risperidone, or haloperidol.	fmph	90-94	caspase 1	Homo sapiens	157-166
35615587-6	2022	Co-treatment with a histamine H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine (FMPH), dose-dependently reduced the increased expression of NLRP3, caspase-1 and GSDMD induced by olanzapine, quetiapine, risperidone, or haloperidol.	fmph	90-94	gasdermin D	Homo sapiens	171-176
35166735-4	2022	FMPH reduced the serum LPS level, increased intestinal ZO-1 and occludin expression, inhibited NF-kappaB phosphorylation, and reduced the levels of TNF-alpha and IL-6.	fmph	0-4	tight junction protein 1	Mus musculus	55-59
35166735-4	2022	FMPH reduced the serum LPS level, increased intestinal ZO-1 and occludin expression, inhibited NF-kappaB phosphorylation, and reduced the levels of TNF-alpha and IL-6.	fmph	0-4	occludin	Mus musculus	64-72
35166735-4	2022	FMPH reduced the serum LPS level, increased intestinal ZO-1 and occludin expression, inhibited NF-kappaB phosphorylation, and reduced the levels of TNF-alpha and IL-6.	fmph	0-4	tumor necrosis factor	Mus musculus	148-157
35166735-4	2022	FMPH reduced the serum LPS level, increased intestinal ZO-1 and occludin expression, inhibited NF-kappaB phosphorylation, and reduced the levels of TNF-alpha and IL-6.	fmph	0-4	interleukin 6	Mus musculus	162-166
35166735-5	2022	Further, FMPH inhibited Th17 cell differentiation, and inhibited inflammasome activation and IL-1beta expression through the NLRP3/ASC/caspase-1 pathway.	fmph	9-13	interleukin 1 alpha	Mus musculus	93-101
35166735-5	2022	Further, FMPH inhibited Th17 cell differentiation, and inhibited inflammasome activation and IL-1beta expression through the NLRP3/ASC/caspase-1 pathway.	fmph	9-13	NLR family, pyrin domain containing 3	Mus musculus	125-130
35166735-5	2022	Further, FMPH inhibited Th17 cell differentiation, and inhibited inflammasome activation and IL-1beta expression through the NLRP3/ASC/caspase-1 pathway.	fmph	9-13	steroid sulfatase	Mus musculus	131-134
35166735-5	2022	Further, FMPH inhibited Th17 cell differentiation, and inhibited inflammasome activation and IL-1beta expression through the NLRP3/ASC/caspase-1 pathway.	fmph	9-13	caspase 1	Mus musculus	135-144
33166570-7	2021	Furthermore, mice pre-treated with all these histaminergic agents except histamine H1 receptor agonist, FMPH shows exacerbated expression to post-nicotine withdrawal induced total abstinence (somatic) score in mice.	fmph	104-108	histamine receptor H1	Mus musculus	73-94
29309856-7	2018	injection of histaminergic agents concomitantly with caffeine during induction phase i.e. histamine H1 receptor agonist, FMPH (6.5 mug/mouse) significantly potentiated while H1 receptor antagonist, cetirizine (0.1 mug/mouse) attenuated the locomotor sensitization induced by caffeine (15 mg/kg, i.p.).	fmph	121-125	histamine receptor H1	Mus musculus	90-111
11812538-4	2002	The histamine-N-methyltransferase (HMT) inhibitor, metoprine (5 and 20 mg/kg s.c.), also decreased the time in the light at the highest dose used and, likewise, the highly selective histamine H(1)-receptor agonist, 2-(3-trifluoromethylphenyl)histamine (FMPH) (2.65 and 6.5 microg/mouse, i.c.v.).	fmph	253-257	histamine N-methyltransferase	Mus musculus	4-33
11812538-4	2002	The histamine-N-methyltransferase (HMT) inhibitor, metoprine (5 and 20 mg/kg s.c.), also decreased the time in the light at the highest dose used and, likewise, the highly selective histamine H(1)-receptor agonist, 2-(3-trifluoromethylphenyl)histamine (FMPH) (2.65 and 6.5 microg/mouse, i.c.v.).	fmph	253-257	histamine N-methyltransferase	Mus musculus	35-38